Cerebrospinal Fluid Abacavir Concentrations in HIV-positive Patients Following Once-daily Administration
| Autor: | Calcagno, A., Pinnetti, C., De Nicolò, A., Scarvaglieri, E., Gisslen, M., Tempestilli, M., D'Avolio, A., Fedele, V., Di Perri, G., Antinori, A., Bonora, S. |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2018 |
| Předmět: |
Adult
Male Time Factors Anti-HIV Agents abacavir protease inhibitors virus diseases HIV Infections Middle Aged central nervous system Dideoxynucleosides Drug Administration Schedule cerebrospinal fluid age pharmacokinetics Treatment Outcome Short Reports Italy immune system diseases Tandem Mass Spectrometry Humans Female Drug Monitoring Chromatography High Pressure Liquid |
| Popis: | Abacavir is a widely used nucleotide reverse transcriptase inhibitor, for which cerebrospinal fluid (CSF) exposure has been previously assessed in twice‐daily recipients. We studied abacavir CSF concentrations in 61 and nine HIV‐positive patients taking abacavir once daily and twice daily, respectively. Patients on once‐daily abacavir had higher plasma and CSF concentrations (96 vs. 22 ng ml(−1), P = 0.038 and 123 vs. 49 ng ml(−1), P = 0.038) but similar CSF‐to‐plasma ratios (0.8 vs. 0.5, P = 0.500). CSF abacavir concentrations were adequate in patients receiving once‐daily treatment. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|